Kawasaki disease (KD) is a medium vessel systemic vasculitis that predominantly occurs in children below five years of age. It is an acute febrile condition in which coronary artery aneurysms and myocarditis are the most common cardiovascular complications. It is most often characterized by hypercytokinemia. The etiopathogenesis of KD is not fully understood. The present review synthesizes the recent advances in the pathophysiology and treatment options of KD. According to different studies, the genetic, infections and autoimmunity factors play a major role in pathogenesis. Several susceptibility genes (e.g. caspase 3) and cytokines (e.g. IL-2, IL-4, IL-6, IL-10, IFN-gamma and TNF-alpha) have been identified in KD. Patients with high cytokine levels are predisposed to KD shock syndrome. The importance of respiratory viruses in the pathogenesis of the disease is unclear. Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may induce in children and adults an abnormal systemic inflammatory response. This syndrome shares characteristics with KD. It has been called by many terms like MIS-C (Multisystem Inflammatory Syndrome in Children), PIMS-TS (pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2), hyperinflammatory shock syndrome, cytokine storm (cytokine release syndrome) or simply, Kawasaki-like syndrome. The cytokine's role in the development of KD or Kawasaki-like syndrome being triggered by COVID-19 is controversial. The presences of the antiendothelial cell autoantibodies (AECAs) together with the newly developed hypothesis of immunothrombosis are considered potential pathogenic mechanisms for KD. In consequence, the diagnosis and treatment of KD and Kawasaki-like syndrome, one of the most common causes of acquired heart disease in developed countries, are challenging without a clearly defined protocol.

Emergency Hospital for Children Cluj Napoca Romania; Department of Immunology Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca Romania and Department of Public Health and Hygiene Faculty of Medicine P J Šafárik University Košice Slovak Republic

Zobrazit více v PubMed

Kawasaki T. Kawasaki disease. Proc Jpn Acad Ser B Phys Biol Sci. 2006;82:59–71. doi: 10.2183/pjab.82.59. PubMed DOI PMC

Kawasaki T. Acute febrile mucocutaneous lymph node syndrome with specific desquamation of the fingers and toes. (Article in Japanese) Arerugi. 1967;16:178–222. PubMed

Son MB, Sundel RP. Kawasaki disease. Textbook of Pediatric Rheumatology. ScienceDirect. 2016:467–483.e6. doi: 10.1016/B978-0-323-24145-8.00035-1. DOI

Holman RC, Belay ED, Christensen KY. Hospitalizations for Kawasaki syndrome among children in the United States, 1997–2007. Pediatr Infect Dis J. 2010;29:483–488. doi: 10.1097/INF.0b013e3181cf8705. PubMed DOI

Yeung RS. Kawasaki disease: update on pathogenesis. Curr Opin Rheumatol. 2010;22:551–560. doi: 10.1097/BOR.0b013e32833cf051. PubMed DOI

Witt MT, Minich LL, Bohnsack JF, Young PC. Kawasaki disease: more patients are being diagnosed who do not meet American Heart Association criteria. Pediatrics. 1999;104:e10. doi: 10.1542/peds.104.1.e10. PubMed DOI

Pinches H, Dobbins K, Cantrell S, May J, Lopreiato J. Asymptomatic Kawasaki disease in a 3-month-old infant. Pediatrics. 2016;138:e20153936. doi: 10.1542/peds.2015-3936. PubMed DOI

Belayneh DK, Calais F. Asymptomatic giant right coronary artery aneurysm in Kawasaki disease: A case report. Clinical case reports. 2020;8:2732–2738. doi: 10.1002/ccr3.3259. PubMed DOI PMC

Agarwal S, Agrawal DK. Kawasaki disease: Etiopathogenesis and novel treatment strategies. Expert Rev Clin Immunol. 2017;13:247–258. doi: 10.1080/1744666X.2017.1232165. PubMed DOI PMC

Shulman ST, Rowley AH. Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol. 2015;11:475–482. doi: 10.1038/nrrheum.2015.54. PubMed DOI

Bustos BR, Jaramillo-Bustamante JC, Vasquez-Hoyos P, Cruces P, Díaz F. Pediatric inflammatory multisystem syndrome associated with SARS-CoV-2: A case series quantitative systematic review. Pediatr Emerg Care. 2021;37:44–47. doi: 10.1097/PEC.0000000000002306. PubMed DOI PMC

Perez-Toledo M, Faustini SE, Jossi SE, Shields AM, Kanthimathinathan HK, Allen JD, Watanabe Y, Goodall M, Wraith DC, Veenith TV, Drayson MT, Jyothish D, Al-Abadi E, Chikermane A, Welch SB, Masilamani K, Hackett S, Crispin M, Scholefield BR, Cunningham AF, Richter AG. Serology confirms SARS-CoV-2 infection in PCR-negative children presenting with paediatric inflammatory multi-system syndrome. medRxiv. 2020 doi: 10.1101/2020.06.05.20123117. 2020.06.05.20123117. DOI

Rowley AH. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol. 2020;20:453–454. doi: 10.1038/s41577-020-0367-5. PubMed DOI PMC

Dos Santos BS, Dos Santos FS, Ribeiro ER. Clinical-epidemiological relation between sars-cov-2 and Kawasaki disease: An integrative literature. (Article in Portuguese, English) Rev Paul Pediatr. 2021;39:e2020217. doi: 10.1590/1984-0462/2021/39/2020217. PubMed DOI PMC

Lin MT, Wu MH. The global epidemiology of Kawasaki disease: Review and future perspectives. Glob Cardiol Sci Pract. 2017;2017:e201720. doi: 10.21542/gcsp.2017.20. PubMed DOI PMC

Makino N, Nakamura Y, Yashiro M, Ae R, Tsuboi S, Aoyama Y, Kojo T, Uehara R, Kotani K, Yanagawa H. Descriptive epidemiology of Kawasaki disease in Japan, 2011–2012: from the results of the 22nd nationwide survey. J Epidemiol. 2015;25:239–245. doi: 10.2188/jea.JE20140089. PubMed DOI PMC

Kim GB, Park S, Eun LY, Han JW, Lee SY, Yoon KL, Yu JJ, Choi JW, Lee KY. Epidemiology and clinical features of Kawasaki disease in South Korea, 2012–2014. Pediatr Infect Dis J. 2017;36:482–485. doi: 10.1097/INF.0000000000001474. PubMed DOI

Wu MH, Lin MT, Chen HC, Kao FY, Huang SK. Postnatal risk of acquiring Kawasaki disease: A nationwide birth cohort database study. J Pediatr. 2017;180:80–6. doi: 10.1016/j.jpeds.2016.09.052. PubMed DOI

Salo E, Griffiths EP, Farstad T, Schiller B, Nakamura Y, Yashiro M, Uehara R, Best BM, Burns JC. Incidence of Kawasaki disease in northern European countries. Pediatr Int. 2012;54:770–72. doi: 10.1111/j.1442-200X.2012.03692.x. PubMed DOI PMC

Burns JC, Herzog L, Fabri O, Tremoulet AH, Rodó X, Uehara R, Burgner D, Bainto E, Pierce D, Tyree M, Cayan D. Seasonality of Kawasaki disease: A global perspective. PLoS One. 2013;8:e74529. doi: 10.1371/journal.pone.0074529. PubMed DOI PMC

Kao AS, Getis A, Brodine S, Burns JC. Spatial and temporal clustering of Kawasaki syndrome cases. Pediatr Infect Dis J. 2008;27:981–985. doi: 10.1097/INF.0b013e31817acf4f. PubMed DOI PMC

Onouchi Y, Fukazawa R, Yamamura K, Suzuki H, Kakimoto N, Ebata R, Higashi K, Tanaka T. Variations in ORAI1 gene associated with Kawasaki disease. PLoS One. 2016;11:e0145486. doi: 10.1371/journal.pone.0145486. PubMed DOI PMC

Onouchi Y. The genetics of Kawasaki disease. Int J Rheum Dis. 2018;21:26–30. doi: 10.1111/1756-185X.13218. PubMed DOI

Padilla LA, Collins JL, Idigo AJ, Lau Y, Portman MA, Shrestha S. Kawasaki disease and clinical outcome disparities among black children. J Pediatr. 2021;229:54–60.e2. doi: 10.1016/j.jpeds.2020.09.052. PubMed DOI PMC

Sakurai Y. Autoimmune aspects of Kawasaki disease. J Investig Allergol Clin Immunol. 2019;29:251–261. doi: 10.18176/jiaci.0300. PubMed DOI

Tirelli F, Marrani E, Giani T, Cimaz R. One year in review: Kawasaki disease. Curr Opin Rheumatol. 2020;32:15–20. doi: 10.1097/BOR.0000000000000671. PubMed DOI

Elakabawi K, Lin J, Jiao F, Guo N, Yuan Z. Kawasaki disease: Global burden and genetic background. Cardiol Res. 2020;11:9–14. doi: 10.14740/cr993. PubMed DOI PMC

Abrams JY, Weintraub ES, Baggs JM, McCarthy NL, Schonberger LB, Lee GM, Klein NP, Belongia EA, Jackson ML, Naleway AL, Nordin JD, Hambidge SJ, Belay ED. Childhood vaccines and Kawasaki disease. Vaccine Safety Datalink, 1996–2006. Vaccine. 2015;33:382–387. doi: 10.1016/j.vaccine.2014.10.044. PubMed DOI

L’Huillier AG, Brito F, Wagner N, Cordey S, Zdobnov E, Posfay-Barbe KM, Kaiser L. Identification of viral signatures using high-throughput sequencing on blood of patients with Kawasaki disease. Front Pediatr. 2019;7:524. doi: 10.3389/fped.2019.00524. PubMed DOI PMC

Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20:3328. doi: 10.3390/ijms20133328. PubMed DOI PMC

Alphonse MP, Duong TT, Shumitzu C, Hoang TL, McCrindle BW, Franco A, Schurmans S, Philpott DJ, Hibberd ML, Burns J, Kuijpers TW, Yeung RSM. Inositol-triphosphate 3-kinase C mediates inflammasome activation and treatment response in Kawasaki disease. J Immunol. 2016;197:3481–3489. doi: 10.4049/jimmunol.1600388. PubMed DOI

Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477–489. doi: 10.1038/s41577-019-0165-0. PubMed DOI PMC

Rife E, Gedalia A. Kawasaki disease: An update. Curr Rheumatol Rep. 2020;22:75. doi: 10.1007/s11926-020-00941-4. PubMed DOI PMC

Rodó X, Ballester J, Cayan D, Melish ME, Nakamura Y, Uehara R, Burns JC. Association of Kawasaki disease with tropospheric wind patterns. Sci Rep. 2011;1:152. doi: 10.1038/srep00152. PubMed DOI PMC

Jorquera H, Borzutzky A, Hoyos-Bachiloglu R, García A. Association of Kawasaki disease with tropospheric winds in Central Chile: is wind-borne desert dust a risk factor? Environ Int. 2015;78:32–38. doi: 10.1016/j.envint.2015.02.007. PubMed DOI

Jaggi P, Kajon AE, Mejias A, Ramilo O, Leber A. Human adenovirus infection in Kawasaki disease: A confounding bystander? Clin Infect Dis. 2013;56:58–64. doi: 10.1093/cid/cis807. PubMed DOI PMC

Turnier JL, Anderson MS, Heizer HR, Jone PN, Glodé MP, Dominguez SR. Concurrent respiratory viruses and Kawasaki disease. Pediatrics. 2015;136:e609–614. doi: 10.1542/peds.2015-0950. PubMed DOI

Gallizzi R, Corsello G, Pajno GB. Kawasaki disease epidemic: Pitfalls. Ital J Pediatr. 2020;46:121. doi: 10.1186/s13052-020-00887-4. PubMed DOI PMC

Ouldali N, Pouletty M, Mariani P, Beyler C, Blachier A, Bonacorsi S, Danis K, Chomton M, Maurice L, Le Bourgeois F, Caseris M, Gaschignard J, Poline J, Cohen R, Titomanlio L, Faye A, Melki I, Meinzer U. Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis. Lancet Child Adolesc Health. 2020;4:662–668. doi: 10.1016/S2352-4642(20)30175-9. PubMed DOI PMC

Alizargar J. The novel coronavirus (COVID-19) and the risk of Kawasaki disease in children. J Formos Med Assoc. 2020;119:1713–1714. doi: 10.1016/j.jfma.2020.05.030. PubMed DOI PMC

Akca UK, Kesici S, Ozsurekci Y, Aykan HH, Batu ED, Atalay E, Demir S, Sag E, Vuralli D, Bayrakci B, Bilginer Y, Ozen S. Kawasaki-like disease in children with COVID-19. Rheumatol Int. 2020;40:2105–2115. doi: 10.1007/s00296-020-04701-6. PubMed DOI PMC

Sakurai Y. Autoimmune aspects of Kawasaki disease. J Investig Allergol Clin Immunol. 2019;29:251–261. doi: 10.18176/jiaci.0300. PubMed DOI

Lindquist ME, Hicar MD. B cells and antibodies in Kawasaki disease. Int J Mol Sci. 2019;20:1834. doi: 10.3390/ijms20081834. PubMed DOI PMC

Kim KY, Kim DS. Recent advances in Kawasaki disease. Yonsei Med J. 2016;57:15–21. doi: 10.3349/ymj.2016.57.1.15. PubMed DOI PMC

Fujieda M, Oishi N, Kurashige T. Antibodies to endothelial cells in Kawasaki disease lyse endothelial cells without cytokine pretreatment. Clin Exp Immunol. 1997;107:120–26. doi: 10.1046/j.1365-2249.1997.d01-894.x. PubMed DOI PMC

Praprotnik S, Rozman B, Blank M, Shoenfeld Y. Pathogenic role of anti-endothelial cell antibodies in systemic vasculitis. Wien Klin Wochenschr. 2000;112:660–664. PubMed

Yap CY, Lin LH, Wang NK. An atypical presentation of Kawasaki disease: A 10-year-old boy with acute exudative tonsillitis and bilateral cervical lymphadenitis. Clinics (Sao Paulo) 2012;67:689–692. doi: 10.6061/clinics/2012(06)25. PubMed DOI PMC

Saguil A, Fargo M, Grogan S. Diagnosis and management of Kawasaki disease. Am Fam Physician. 2015;91:365–371. PubMed

Cotts TB. AHA Scientific Statement on Kawasaki Disease. American College of Cardiology; Apr 21, 2017. https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/04/21/11/45/diagnosis-treatment-and-long-term-management-of-kawasaki-disease .

McCrindle BW, Cifra B. The role of echocardiography in Kawasaki disease. Int J Rheum Dis. 2018;21:50–5. doi: 10.1111/1756-185X.13216. PubMed DOI

Qiu H, Li C, He Y, Weng F, Shi H, Pan L, Guo Y, Zhang Y, Wu R, Chu M. Association between left ventricular ejection fraction and Kawasaki disease shock syndrome. Cardiol Young. 2019;29:178–184. doi: 10.1017/S1047951118002056. PubMed DOI

Kanegaye JT, Wilder MS, Molkara D, Frazer JR, Pancheri J, Tremoulet AH, Watson VE, Best BM, Burns JC. Recognition of a Kawasaki disease shock syndrome. Pediatrics. 2009;123:e783–789. doi: 10.1542/peds.2008-1871. PubMed DOI PMC

Lo Mindy S, Newburger JW. Role of intravenous immunoglobulin in the treatment of Kawasaki disease. Int J Rheum Dis. 2018;21:64–69. doi: 10.1111/1756-185X.13220. PubMed DOI

Fuller MG. Kawasaki disease in infancy. Adv Emerg Nurs J. 2019;4:222–228. doi: 10.1097/TME.0000000000000253. PubMed DOI

Dhanrajani A, Chan M, Pau S, Ellsworth J, Petty R. Aspirin dose in Kawasaki disease: The ongoing battle. Arthritis Care Res (Hoboken) 2018;70:1536–1540. doi: 10.1002/acr.23504. PubMed DOI

Ito Y, Matsui T, Abe K, Honda T, Yasukawa K, Takanashi JI, Hamada H. Aspirin dose and treatment outcomes in Kawasaki disease: A historical control study in Japan. Front Pediatr. 2020;8:249. doi: 10.3389/fped.2020.00249. PubMed DOI PMC

Takeshita S, Kawamura Y, Nakatani K, Tsujimoto H, Tokutomi T. Standard-dose and short-term corticosteroid therapy in immunoglobulin-resistant Kawasaki disease. Clin Pediatr (Phila) 2005;44:423–426. doi: 10.1177/000992280504400507. PubMed DOI

Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics. 2012;129:e17–23. doi: 10.1542/peds.2011-0148. PubMed DOI

Tremoulet AH. Adjunctive therapies in Kawasaki disease. Int J Rheum Dis. 2018;21:76–79. doi: 10.1111/1756-185X.13208. PubMed DOI PMC

Phuong LK, Curtis N, Gowdie P, Akikusa J, Burgner D. Treatment options for resistant Kawasaki disease. Paediatr Drugs. 2018;20:59–80. doi: 10.1007/s40272-017-0269-6. PubMed DOI

Rao S, Sasser W, Diaz F, Sharma N, Alten J. Coronavirus associated fulminant myocarditis successfully treated with intravenous immunoglobulin and extracorporeal membrane oxygenation. Chest. 2014;146:336A. doi: 10.1378/chest.1992018. DOI

Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. 2020;5:751–753. doi: 10.1001/jamacardio.2020.1105. PubMed DOI

Blondiaux E, Parisot P, Redheuil A, Tzaroukian L, Levy Y, Sileo C, Schnuriger A, Lorrot M, Guedj R, Le Pointe HD. Cardiac MRI of children with multisystem inflammatory syndrome (MIS-C) associated with COVID-19. Radiology. 2020;297:E283–E288. doi: 10.1148/radiol.2020202288. PubMed DOI PMC

Kiss A, MacDaragh Ryan P, Mondal T. Management of COVID-19-associated multisystem inflammatory syndrome in children: A comprehensive literature review. Prog Pediatr Cardiol. 2021;9:101381. doi: 10.1016/j.ppedcard.2021.101381. PubMed DOI PMC